Form 8-K - Current report:
SEC Accession No. 0001628280-25-008873
Filing Date
2025-02-28
Accepted
2025-02-28 08:02:28
Documents
15
Period of Report
2025-02-28
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K prme-20250228.htm   iXBRL 8-K 27563
2 EX-99.1 a02-28x2025xpressrelease.htm EX-99.1 61346
6 imagea.jpg GRAPHIC 8641
  Complete submission text file 0001628280-25-008873.txt   237457

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT prme-20250228.xsd EX-101.SCH 1800
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT prme-20250228_lab.xml EX-101.LAB 22531
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT prme-20250228_pre.xml EX-101.PRE 13055
17 EXTRACTED XBRL INSTANCE DOCUMENT prme-20250228_htm.xml XML 2913
Mailing Address 60 FIRST ST. CAMBRIDGE MA 02141
Business Address 60 FIRST ST. CAMBRIDGE MA 02141 617-465-0013
Prime Medicine, Inc. (Filer) CIK: 0001894562 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41536 | Film No.: 25682800
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)